Fulvestrant Run-In
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ER-Positive Breast Cancer
Conditions
ER-Positive Breast Cancer, HER2-negative Breast Cancer
Trial Timeline
Feb 25, 2021 → Dec 1, 2027
NCT ID
NCT05305924About Fulvestrant Run-In
Fulvestrant Run-In is a phase 2 stage product being developed by Eli Lilly for ER-Positive Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05305924. Target conditions include ER-Positive Breast Cancer, HER2-negative Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05305924 | Phase 2 | Recruiting |
Competing Products
6 competing products in ER-Positive Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + Ribociclib | AstraZeneca | Phase 3 | 77 |
| AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonist | AstraZeneca | Phase 3 | 77 |
| [14C]AZD9833 Oral Solution, 75 mg | AstraZeneca | Phase 1 | 33 |
| AZD9833 + Fulvestrant | AstraZeneca | Phase 2 | 52 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 41 |
| Onapristone + Fulvestrant | Context Therapeutics | Phase 2 | 44 |